Top

Published in:

Open Access 01-03-2019 | Original Article

Salivary levels and immunohistochemical expression of selected angiogenic factors in benign and malignant parotid gland tumours

Authors: Katarzyna Błochowiak, Jerzy Sokalski, Ewelina Golusińska, Dorota Trzybulska, Henryk Witmanowski, Magdalena Bodnar, Andrzej Marszałek

Published in: Clinical Oral Investigations | Issue 3/2019

Abstract

Objectives

Angiogenesis underlies tumour growth and metastasis through hepatocyte growth factor (HGF), epithelial growth factor (EGF), and vascular endothelial growth factor (VEGF). The aim of this study was to determine the levels of VEGF, EGF, HGF, HGFR (hepatocyte growth factor receptor), and SRSF1 (serine-rich protein splicing factor-1) in patients with parotid gland tumours and in healthy controls via ELISA in parotid saliva. Immunohistochemical expression of anti-angiogenic isoform of VEGF₁₆₅b subunit, VEGFR1, VEGFR2, and microvessel density (CD34) were assessed in the tumour tissue and in the non-tumorous surrounding margins.

Materials and methods

The study included 48 patients with benign and malignant parotid gland tumours and 15 healthy controls.

Results

Comparison of VEGF, EGF, and HGF in tumour and non-tumorous tissues showed no significant differences and no correlations with tumour stage. The salivary VEGF concentration was significantly higher in patients with pleomorphic adenoma and Warthin’s tumour. No significant correlation was found between expression of VEGF₁₆₅b and VEGFR2 in tumours and non-tumor surgical margins.

Conclusions

The increased salivary VEGF reflects changes in affected parotid glands, but it cannot be used as a prognostic and differentiative factor for parotid tumours.

Clinical relevance

Reciprocal relations between growth factors suggest an overlapping pathway of secretion and activity.

Lim JJ, Kang S, Lee MR, Pai HK, Yoon HJ, Lee JI, Hong SP, Lim CY (2003) Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis. J Oral Pathol Med 32:552–561PubMed

Prenen H, Kimpe M, Nuyts S (2008) Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets. Curr Opin Oncol 20:270–274CrossRefPubMed

Lequerica-Fernández P, Astudillo A, De Vicente JC (2007) Expression of vascular endothelial growth factor in salivary gland carcinomas correlates with lymph node metastasis. Anti Cancer Res 27:3661–3666

Ho K, Lin H, Ann DK, Chu PG, Yen Y (2011) An overview of the rare parotid gland cancer. Head Neck Oncol 3:40CrossRefPubMedPubMedCentral

Li H, Nong X, Chen Q, Yang Y, Li J, Li Y (2010) Nerve growth factor and vascular endothelial growth factor: retrospective analysis of 63 patients with salivary adenoid cystic carcinoma. Int J Oral Sci 2:35–44CrossRefPubMedCentral

Tsukinoki K, Yasuda M, Asano S, Karakida K, Ota Y, Osamura RY, Watanabe Y (2003) Association of hepatocyte growth factor expression with salivary gland tumor differentiation. Pathol Int 3:815–822CrossRef

Younes MN, Park YW, Yazici YD, Gu M, Santillan AA, Nong X, Kim S, Jasser SA, El-Naggar AK, Myers JN (2006) Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther 5:2696–2705CrossRefPubMed

de Faria PR, Lima RA, Dias FL, de Faria PAS, Amaral Eisenberg AL, do Nascimento Souza KC, Cardoso SV, Loyola AM (2011) Vascular endothelial growth factor and thymidine phosphorylase expression in salivary gland tumors with distinct metastatic behaviour. J Oral Pathol Med 40:456–459CrossRefPubMed

Swelam W, Ida-Yonemochi H, Maruyama S, Ohshiro K, Cheng J, Saku T (2005) Vascular endothelial growth factor in salivary pleomorphic adenomas: one of the reasons for their poorly vascularized stroma. Virchows Arch 446:653–662CrossRefPubMed

10.

Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ, Bates DO (2008) Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. J Cell Sci 121:3487–3495CrossRefPubMed

11.

Dokun AO, Annex BH (2011) The VEGF₁₆₅b “ICE-o-form” puts a chill on the VEGF story. Circ Res 109:246–247CrossRefPubMedPubMedCentral

12.

Qiu Y, Ferguson J, Oltean S, Neal CR, Kaura A, Bevan H, Wood E, Sage LM, Lanati S, Nowak DG, Salmon AHJ, Bates D, Harper SJ (2010) Overexpression of VEGF₁₆₅b in podocytes reduces glomerular permeability. J Am Soc Nephrol 21:1498–1509CrossRefPubMedPubMedCentral

13.

Wollard J, Wang WY, Bevan HS et al (2004) VEGF₁₆₅b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 64:7822–7835CrossRef

14.

Tayama M, Furuhata T, Inafuku Y, Okita K, Nishidate T, Mizuguchi T, Kimura Y, Hirata K (2011) Vascular endothelial growth factor 165b expression in stromal cells and colorectal cancer. World J Gastroenterol 17:4867–4874CrossRefPubMedPubMedCentral

15.

Rennel ES, Waine E, Guan H, Schüler Y, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman ES, Bates DO, Harper SJ (2008) The endogenous anti-angiogenic VEGF isoform, VEGF ₁₆₅b inhibits human tumour growth in mice. Br J Cancer 98:1250–1257CrossRefPubMedPubMedCentral

16.

Rennel ES, Hamdollah-Zadeh MA, Wheatley ER, Magnussen A, Schüler Y, Kelly SP, Finucane C, Ellison D, Cebe-Suarez S, Ballmer-Hofer K, Mather S, Stewart L, Bates DO, Harper SJ (2008) Recombinant human VEGF₁₆₅b protein is an effective anti-cancer agent in mice. Eur J Cancer 44:1883–1894CrossRefPubMedPubMedCentral

17.

Díaz R, Peña C, Silva J, Lorenzo Y, García V, García JM, Sánchez A, Espinosa P, Yuste R, Bonilla F, Domínguez G (2008) p73 isoforms affect VEGF, VEGF₁₆₅b and PEDF expression in human colorectal tumors: VEGF₁₆₅b downregulation as a marker of poor prognosis. Int J Cancer 123:1060–1067CrossRefPubMed

18.

Kukreja I, Kapoor P, Deshimukh R, Kulkarni V (2013) VEGF and CD34: a correlation between tumor angiogenesis and microvessel density-an immunohistochemical study. J Oral Maxillofac Pathol 3:367–373

19.

Muhammadnejad S, Muhammadnejad A, Haddadi M, Oghabian MA, Mohagheghi MA, Tirgari F, Sadeghi-Fazel F, Amanpour S (2013) Correlation of microvessel dentisy with nuclear pleomorphic, mitotic count and vascular invasion in breast and prostate cancers at preclinical and clinical levels. Asian Pac J Cancer Prev 14:63–68CrossRefPubMed

20.

Edge SB, Compton CC (2010) The American Joint Committee on cancer the 7^th edition of the AJCC cancer staging manual and future of TNM. Ann Surg Oncol 17:1471–1474CrossRefPubMed

21.

Bodnar M, Szylberg Ł, Kaźmierczak W, Marszałek A (2013) Differentiated expression of membrane type metalloproteinases (MMP-14, MMP-15) and pro-MMP2 in laryngeal squamous cell carcinoma. A novel mechanism. J Oral Pathol Med 42:267–274CrossRefPubMed

22.

Burduk PK, Bodnar M, Sawicki P, Szylberg Ł, Wiśniewska E, Kazimierczak W, Martyńska M, Marszałek A (2015) Expression of metalloproteinases 2 and 9 and tissue inhibitors 1 and 2 as predictors of lymph node metastases in oropharyngeal squamous cell carcinoma. Head Neck 37:418–422CrossRefPubMed

23.

Andisheh Tadbir A, Khademi B, Kamali F, Fattahi MJ, Malekzadeh M, Taghva M (2014) Upregulation of serum vascular endothelial growth factor and matrix metalloproteinase-3 in patients with oral squamous cell carcinoma. Tumor Biol 35:5689–5693CrossRef

24.

Andisheh Tadbir A, Khademi B, Malekzadeh M, Mardani M, Khadeni B (2013) Upregulation of serum vascular endothelial growth factor in patients with salivary gland tumor. Pathol Res Int Article ID 740582

25.

Teknos TN, Cox C, Yoo S, Chepeha DB, Wolf GT, Bradford CR, Carey TE, Fisher SG (2002) Elevated serum vascular endothelial growth factor and decreased survival in advanced laryngeal carcinoma. Head Neck 24:1004–1011CrossRefPubMed

26.

Shang ZJ, Li JR, Li ZB (2002) Circulating levels of vascular endothelial growth factor in patients with oral squamous cell carcinoma. Int J Oral Maxillofac Surg 31:495–498CrossRefPubMed

27.

Vered M, Braunstein E, Buchner A (2002) Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin. Head Neck 24:632–636CrossRefPubMed

28.

Monteiro LS, Bento MJ, Palmeira C, Lopes C (2009) Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours. J Oral Pathol Med 38:508–513CrossRefPubMed

29.

Myoken Y, Myoken Y, Okamoto T, SaTo JD, Kan M, McKeehan WL, Nakahara M, Takada K (1996) Immunohistochemical study of overexpression of fibroblast growth factor-1 (FGF-1), FGF-2, and FGF receptor-1 in human malignant salivary gland tumours. 196;178:429–36

30.

Ustuner Z, Saip P, Yasasever V, Vural B, Yazar A, Bal C, Ozturk B, Ozbek U, Topuz E (2008) Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients. Med Oncol 25:394–399CrossRefPubMed

Title: Salivary levels and immunohistochemical expression of selected angiogenic factors in benign and malignant parotid gland tumours
Authors: Katarzyna Błochowiak
Jerzy Sokalski
Ewelina Golusińska
Dorota Trzybulska
Henryk Witmanowski
Magdalena Bodnar
Andrzej Marszałek
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Published in: Clinical Oral Investigations / Issue 3/2019
Print ISSN: 1432-6981
Electronic ISSN: 1436-3771
DOI: https://doi.org/10.1007/s00784-018-2524-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Salivary levels and immunohistochemical expression of selected angiogenic factors in benign and malignant parotid gland tumours

Abstract

Objectives

Materials and methods

Results

Conclusions

Clinical relevance

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objectives

Materials and methods

Results

Conclusions

Clinical relevance

Please log in to get access to this content

Other articles of this Issue 3/2019

Intratubular decontamination ability and physicochemical properties of calcium hydroxide pastes

Salivary adiponectin, but not adenosine deaminase, correlates with clinical signs in women with Sjögren’s syndrome: a pilot study

Bone tissue reaction, setting time, solubility, and pH of root repair materials

Is the pneumatisation of the maxillary sinus following tooth loss a reality? A retrospective analysis using cone beam computed tomography and a customised software program

Injectable platelet rich fibrin: cell content, morphological, and protein characterization

A comparison of orofacial profiles in 5- and 10-year-old Swedish children with and without cleft lip and/or palate